Amyloid protein clearance

The term "amyloid protein clearance" refers to the diverse collection of biological mechanisms by which the brain removes amyloid-β (Aβ), the peptide central to Alzheimer’s disease pathogenesis. This is not a single molecule or canonical drug target but rather an ensemble of processes involving multiple proteins, enzymes, transporters, and cell types. Key partitioned mechanisms include enzymatic degradation of Aβ by proteases such as neprilysin (NEP), insulin-degrading enzyme (IDE), and endothelin-converting enzyme (ECE)[4][7], receptor-mediated transcytosis and transport (including LRP1, VLDLR, and P-glycoprotein)[1][7], cellular uptake and phagocytosis by microglia and astrocytes[1][7], lymphatic drainage via perivascular routes[1][7], and autophagic degradation[1]. Failures in these clearance pathways are implicated directly in amyloid accumulation and the neuropathology of Alzheimer’s disease[2][3]. Therefore, the processes collectively termed "amyloid protein clearance" are therapeutic targets, and drugs that facilitate these pathways—including monoclonal antibodies, enzyme enhancers, and secretase inhibitors—are in active clinical development or use[8]. However, since "amyloid protein clearance" names a process rather than a discrete molecule, it is not appropriate as a canonical drug target entry. Because of these features, "amyloid protein clearance" should not be listed as a molecular target, but instead mapped to its specific molecular effectors (e.g., neprilysin, LRP1, microglial receptor, etc.) when assembling structured, target-level drug or pathway data[4][7][2].

Other names

Aβ clearanceamyloid-beta clearanceamyloid protein removalAβ degradationamyloid clearance

Immunotherapy targeting amyloid plaques (monoclonal antibodies), Enzyme activation or gene therapy to enhance protease-mediated degradation, Inhibition of amyloid protein production (BACE and γ-secretase inhibition), Modulation of transporter and receptor function for Aβ clearance